Tadalafil Tablet, Film Coated
Product Images NDC 43598-578

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Tadalafil (NDC 43598-578). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Dr.reddys Laboratories Inc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure3new

A chart illustrating the fold change and 90% confidence interval (CI) of various coadministered drugs relative to their administration alone, with recommendations indicating no dose adjustment for all listed drugs. The chart includes substrates of CYP1A2, CYP2C9, CYP3A, and P-glycoprotein, oral contraceptives, and NSAIDs, showing the change in AUC and Cmax values.*

FDA Label Image

Container (Container)

Label for Tadalafil Tablets, USP 20 mg by Dr. Reddys Laboratories Inc, containing 60 film-coated oral tablets. The label shows the orange oval tablet imprint RDY 20, NDC 43598-578, and includes a QR code linking to the patient information sheet. It states 'Rx Only' and provides storage and usage instructions.*

FDA Label Image

Figure1 (Figure1)

A forest plot chart comparing the mean difference in blood pressure variables between tadalafil 20 mg and placebo when coadministered with various drugs. The horizontal axis represents values from -20 to +20, showing effects lower or higher relative to placebo. Error bars indicate 95% confidence intervals for systolic and diastolic blood pressure changes in standing, supine, or ambulatory positions.*

FDA Label Image

Figure2 (Figure2)

A chart illustrating the fold change and 90% confidence interval of drugs coadministered with Tadalafil, showing the change relative to Tadalafil alone on the horizontal axis. It includes CYP3A inhibitors, CYP3A inducers, antacids, and H2 antagonists, with recommendations for each coadministered drug such as dose adjustment, avoid use, or no dose adjustment.*

FDA Label Image

Figure4

A line graph showing mean change from baseline in meters over a 16-week period, comparing placebo and Tadalafil 40 mg groups. The x-axis represents weeks (0 to 16) and the y-axis shows change in meters. Tadalafil group shows increased improvement over time compared to placebo, with statistical significance indicated at multiple time points.*

FDA Label Image

Figure5

A horizontal forest plot chart comparing placebo and tadalafil 40 mg across various subject subgroups, including bosentan use, PAH etiology, baseline 6-minute walk distance, gender, age, and baseline WHO functional class. The chart shows the number of subjects, point estimates with horizontal confidence intervals around zero, and change values for each subgroup.*

FDA Label Image

Figure6

A survival curve chart showing the percentage of subjects without clinical worsening over time in days. The chart compares three groups: Tadalafil 40 mg, Tadalafil 20 mg, and placebo, illustrating their respective clinical outcomes.*

FDA Label Image

Image2 (Image2)

Tadalafil 20 mg film-coated tablet label by Dr.Reddys Laboratories Inc. The image shows a small white square with 'RDY' and '20' printed in black, indicating the tablet imprint for identification.*

FDA Label Image

Structure (Structure)

Chemical structure of tadalafil, showing its molecular framework including fused rings and functional groups.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.